Associations Between miRNAs and Two Different Cancers: Breast and Colon

Area of Science:

• Oncology
• Molecular Biology
• Biomarker Discovery

Background:

• Aberrant microRNA (miRNA) expression is implicated in cancer development and progression.
• miRNAs are being investigated as potential diagnostic, prognostic, and monitoring tools in oncology.
• Specific miRNAs (miR-21, miR-31, miR-143, miR-145) are differentially expressed in cancer patients.

Purpose of the Study:

• To characterize the expression of miR-21, miR-31, miR-143, and miR-145 in peripheral blood mononuclear cells (PBMCs) of breast and colorectal cancer patients.
• To compare miRNA expression in cancer patients versus healthy controls.
• To evaluate the potential of these miRNAs as tumor markers for breast and colon cancer.

Main Methods:

• Study included 30 breast cancer patients, 30 colorectal cancer patients, and 30 healthy controls.
• Peripheral blood mononuclear cells (PBMCs) were isolated from blood samples.
• miRNA expression was analyzed using a two-step reverse transcription and quantitative polymerase chain reaction (qPCR) method.

Main Results:

• In breast cancer, miR-143 and miR-31 decreased, while miR-145 and miR-21 increased compared to controls.
• In colon cancer, miR-143, miR-145, and miR-21 increased, with no significant change in miR-31.
• miR-21 showed the highest increase in both cancer types; miR-143 correlated with colon cancer TNM stage.

Conclusions:

• A biomarker panel of miR-21, miR-31, miR-143, and miR-145 in PBMCs could offer a new diagnostic approach for early breast and colon cancer detection.
• miR-21, with its elevated expression, is a promising tumor biomarker and potential therapeutic target for breast and colon cancers.